Effect of PPIs on Stool DNA Test for H. Pylori

Recruiting now

Conditions studied: Helicobacter Pylori Infection

In brief

This prospective, self-controlled clinical study aims to evaluate the impact of proton pump inhibitor (PPI) use on the accuracy of stool DNA testing for Helicobacter pylori (H. pylori) and to assess the applicability of this test in patients receiving PPI therapy. Patients requiring long-term PPI treatment and meeting the inclusion criteria were enrolled. After at least four weeks of PPI therapy, a stool DNA test was performed, along with collection of gastric mucosal samples via gastroscopy for tissue PCR, histology, and rapid urease testing, as well as H. pylori antibody detection. Subsequently, PPI treatment was discontinued for four weeks, after which a 13C-urea breath test and a repeat stool DNA test were conducted. By comparing the sensitivity, specificity, and consistency of stool DNA testing before and after PPI discontinuation, this study aims to characterize the interference of PPIs with the test results, thereby providing evidence to support improvements in H. pylori diagnostic methods.

Key facts

Study ID

NCT07516262

Run by

Shanghai Jiao Tong University School of Medicine

People needed

25

Starts

2025-05-01

Expected to finish

2026-06-30

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients aged 18-80 years;
• No prior H. pylori eradication therapy;
• Patients requiring proton pump inhibitor (PPI) therapy in the near future due to gastritis, peptic ulcer disease, or other indicated conditions;
• Patients with at least two positive results among H. pylori antibody test, histology, and rapid urease test (RUT);
• Provision of signed informed consent and being informed of the specific study protocol.

You may not qualify if…

• Prior H. pylori eradication therapy;
• Pregnant or lactating women;
• Acute gastrointestinal bleeding;
• History of subtotal gastrectomy;
• Severe dysfunction of vital organs (heart, liver, kidney, lungs, etc.) or congenital diseases, such as class IV cardiac insufficiency, liver failure, uremia, respiratory failure, hemophilia, Wilson's disease, etc.;
• Refusal of enrollment by the guardian or the patient;
• Alcohol and/or drug abuse (addiction or dependence), or poor compliance as judged by the investigator;
• Individuals without legal capacity or with impaired insight;
• Abnormal neurological signs on physical examination;
• Use of oral antibiotics with bactericidal activity against H. pylori within 4 weeks.

Where it is running

• Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.